15 RESULTS
COMMENT This paper by Norman and colleagues on the use of the L1CAM protein to enrich for “neuron-derived extracellular vesicles” (NDVEs), also called neuronally derived “exosomes,” is an important contribution on methodological aspects in the search for blood ...
COMMENT This is a very interesting and important study. For the first time, it is convincingly shown (at the group level) that former National Fotboll League players, with cognitive and behavioral symptoms, have increased tau PET ligand retention in several ...
COMMENT These results are very promising, and lend further support to the use of blood Aβ as a screening biomarker for brain amyloidosis. The results add to the recent paper published last year that also used immunoprecipitation and mass spectrometry for ...
COMMENT We agree with Dr. Aisen that plasma NfL may potentially be useful as a biomarker for prescreening individuals who are selected for further testing before inclusion in early intervention trials. We think this is one of the most interesting possible future ...
COMMENT This is a nice confirmation of the 1996 Rosengren et al. study that reported that patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. In agreement with that paper, Gaiani ...
COMMENT This is an interesting and important paper on the core AD CSF biomarkers in cognitively normal elderly. Biomarkers are increasingly used for inclusion purposes in clinical trials, to enrich for patients or normal elderly with biomarker evidence of AD ...
COMMENT This is yet another important paper from the Washington University group on the very early evolution of pathogenic processes in AD. We have learned a lot about AD pathogenesis by studying AD biomarkers in cross-sectional studies, often with clinical ...
COMMENT This is an interesting study with large potential, since it identifies a set of candidate AD biomarkers in blood exosomes. The principle of isolating exosomes and quantifying specific candidate protein biomarkers is an attractive approach to identifying ...
COMMENT This is an interesting article, and we agree with its scientific argument. Bart de Strooper is right about the short half-life of semagacestat, and important aspects such as its rebound effect on CSF Aβ levels. Whether this explains the cognitive ...
COMMENT This paper brings up an important topic, namely the uncertainty of current approaches in the preclinical evaluation of novel drug candidates for Alzheimer’s disease. As stated by the authors, many studies have been performed on transfected cell lines and ...
COMMENT This study is an excellent example of the importance of longitudinal biomarker studies in different stages of AD, from the preclinical to the dementia stage. Just as the map of the world was redrawn after the introduction of modern technology, knowledge ...
COMMENT We read with interest the response by Netzer, Greengard, and colleagues. It is clear that we have different views not only on the biological effect of GSAP but also on Αβ (patho)physiology in general. There are some strong claims in the response, e.g., ...
COMMENT We welcome a discussion on the problem with irreproducibility of published research that we recently encountered, as outlined in the Alzforum news story. In this context, the recent editorial guidelines from Nature might represent one step to reduce this ...
COMMENT Genomics and proteomics have become highly active research areas to search for novel genes and proteins involved in disease pathogenesis, or to identify novel biomarkers. Research has also expanded to include other “omics” such as metabolomics and ...
COMMENT FDDNP-PET shows promise for monitoring plaque and tangle pathology in Alzheimer patients Research advances on the molecular pathogenesis of Alzheimer disease (AD) have led to several drug candidates with potential disease-modifying effects, for example, ...
